newsfilter
← Latest News
Business Wire·

Reata Pharmaceuticals Announces Three Month Extension of the Review Period for New Drug Application for Omaveloxolone for the Treatment of Friedreich's Ataxia

Reata Submitted New Data and Analyses to Address FDA Questions During Mid-Cycle Meeting FDA Extended PDUFA Date to Provide Time for Full Review of New Submissions PDUFA Date Extended to February 28, 2023 Reata Pharmaceuticals, Inc. (NASDAQ:RETA